ArticleMolecular and cellular biochemistry2026
USP7-stabilized CEBPB promotes HpSCC progression by upregulating IL6 to activate the JAK2/STAT3 signaling.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCCAAT/enhancer-binding protein B (CEBPB) has been reported as a transcription factor implicated in the occurrence and development of various human tumors. However, its role and mechanism in hypopharyngeal squamous cell carcinoma (HpSCC) remain unclear.
methodsqRT-PCR, western blot, and immunohistochemistry assays were used for mRNA or protein expression in HpSCC tissus or cells. HpSCC cell phenotypes were evaluated using colony formation, EdU, wound healing, and transwell assays. The role of CEBPB in HpSCC tumorigenesis was also investigated by establishing xenograft model in mice. Interaction between CEBPB and ubiquitin-specific peptidase 7 (USP7) was confirmed using co-immunoprecipitation (Co-IP), cycloheximide (CHX) chase, and deubiquitination assays. Chromatin immunoprecipitation (ChIP) and luciferase reporter assays were employed to determine the transcription regulation of CEBPB on IL-6.
resultsHigher CEBPB expression was found in HpSCC tissues and represented a worse prognosis. Knockdown of CEBPB inhibited HpSCC cell proliferation, migration, invasion, and EMT, while overexpression of CEBPB displayed the opposite trend. USP7 stabilized CEBPB protein by its deubiquitination activity. CEBPB binds to the promoter of IL-6 to increase its transcription, thus activating the JAK2/STAT3 signaling pathway. Furthermore, USP7 could promote IL-6 expression through CEBPB. Functionally, restoration of CEBPB expression reversed the anti-cancer effect of USP7 depletion in HpSCC. Moreover, the inhibitory effect of HpSCC progression mediated by CEBPB knockdown was abated upon IL-6 upregulation.
conclusionOur finding reveals a novel USP7/CEBPB/IL-6/JAK2/STAT3 axis in regulating HpSCC progression, targeting this pathway might be a valuable strategy for HpSCC therapy.
Indexed as
Identifiers
42048037What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.